As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Ptc Therapeutics, Inc. The largest reported stake is BlackRock, Inc.'s, at 14.8%. 13 filings are on record since August 14, 2025 (Schedule 13G/A, December 4, 2025).
Sell to companies like Ptc Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Janus Henderson Group Plc · Sole voting: 0 · Shared voting: 7,193,433 · Sole dispositive: 0 · Shared dispositive: 7,193,433 · SCHEDULE 13G/A, 2026-05-15
- · Reporting person: The Toronto-Dominion Bank · Sole voting: 3,025,945 · Shared voting: 0 · Sole dispositive: 3,025,945 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-15
- · Reporting person: Vanguard Capital Management · Sole voting: 608,192 · Shared voting: 0 · Sole dispositive: 4,284,448 · Shared dispositive: 0 · SCHEDULE 13G, 2026-04-30
- · Reporting person: Vanguard Portfolio Management · Sole voting: 66,735 · Shared voting: 0 · Sole dispositive: 4,871,329 · Shared dispositive: 0 · SCHEDULE 13G, 2026-04-29
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
Ptc Therapeutics, Inc. has 13 Schedule 13D or 13G filings on record since 2025-08-14. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 14.8% | 11,904,696 | SCHEDULE 13G/A, 2025-12-04 | 2025-11-30 |
| Janus Henderson Group Plc | 8.7% | 7,193,433 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Vanguard Portfolio Management | 5.88% | 4,871,329 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| State Street Corporation | 5.2% | 4,206,126 | SCHEDULE 13G, 2026-02-09 | 2025-12-31 |
| Vanguard Capital Management | 5.17% | 4,284,448 | SCHEDULE 13G, 2026-04-30 | 2026-03-31 |
| Wellington Management Group LLP | 4.8% | 3,867,380 | SCHEDULE 13G/A, 2026-02-10 | 2025-12-31 |
| Armistice Capital, LLC | 4.08% | 3,277,272 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| The Toronto-Dominion Bank | 3.7% | 3,025,945 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Ptc Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Ptc Therapeutics, Inc. and the records around it.
Ptc Therapeutics, Inc. elsewhere on the record
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- The Toronto-Dominion Bank also filed stake reports on 5 other companies: eBay Inc. (Aug 2026), Stoke Therapeutics, Inc. (Aug 2026), UroGen Pharma Ltd. (Aug 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Ptc Therapeutics, Inc.
Get an email when Ptc Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Ptc Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Ptc Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ptc Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Janus Henderson Group Plc | 0 | 7,193,433 | 0 | 7,193,433 | SCHEDULE 13G/A, 2026-05-15 |
| Vanguard Portfolio Management | 66,735 | 0 | 4,871,329 | 0 | SCHEDULE 13G, 2026-04-29 |
| Vanguard Capital Management | 608,192 | 0 | 4,284,448 | 0 | SCHEDULE 13G, 2026-04-30 |
| The Toronto-Dominion Bank | 3,025,945 | 0 | 3,025,945 | 0 | SCHEDULE 13G/A, 2026-05-15 |
The latest filing identifies Ptc Therapeutics, Inc. by CUSIP 69366J200 and gives its principal executive office as 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ 07059 (SCHEDULE 13G/A, 2026-05-15).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Armistice Capital, LLC | 5.96% | SCHEDULE 13G/A |
| 2025-10-30 | The Vanguard Group | 10.43% | SCHEDULE 13G/A |
| 2025-11-14 | Armistice Capital, LLC | 4.08% | SCHEDULE 13G/A |
| 2025-12-04 | BlackRock, Inc. | 14.8% | SCHEDULE 13G/A |
| 2026-02-09 | State Street Corporation | 5.2% | SCHEDULE 13G |
| 2026-02-10 | Wellington Management Group LLP | 4.8% | SCHEDULE 13G/A |
| 2026-02-13 | The Toronto-Dominion Bank | 5.2% | SCHEDULE 13G |
| 2026-02-17 | Janus Henderson Group Plc | 6% | SCHEDULE 13G |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Vanguard Portfolio Management | 5.88% | SCHEDULE 13G |
| 2026-04-30 | Vanguard Capital Management | 5.17% | SCHEDULE 13G |
| 2026-05-15 | The Toronto-Dominion Bank | 3.7% | SCHEDULE 13G/A |
| 2026-05-15 | Janus Henderson Group Plc | 8.7% | SCHEDULE 13G/A |
Questions about who owns Ptc Therapeutics, Inc.
Who owns Ptc Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Ptc Therapeutics, Inc.: BlackRock, Inc. (14.8%, Schedule 13G/A, filed 2025-12-04), Janus Henderson Group Plc (8.7%, Schedule 13G/A, filed 2026-05-15), Vanguard Portfolio Management (5.88%, Schedule 13G, filed 2026-04-29), State Street Corporation (5.2%, Schedule 13G, filed 2026-02-09) and Vanguard Capital Management (5.17%, Schedule 13G, filed 2026-04-30).
Who are the largest shareholders of Ptc Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Ptc Therapeutics, Inc. on this page are BlackRock, Inc. (14.8%), Janus Henderson Group Plc (8.7%) and Vanguard Portfolio Management (5.88%).
When did BlackRock, Inc. buy into Ptc Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from BlackRock, Inc. on this page is the Schedule 13G/A, filed 2025-12-04, reporting 14.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Ptc Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 30, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| June 9, 2026 | Leadership change: Alethia Young departs, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Ptc Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.